Non Hodgkin's Lymphoma News and Research

RSS
The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.
Houston Methodist researchers join national consortium to develop herpesvirus vaccine

Houston Methodist researchers join national consortium to develop herpesvirus vaccine

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

High BMI in late teens linked to higher risk of 17 different cancers later in life

High BMI in late teens linked to higher risk of 17 different cancers later in life

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

Formerly incarcerated persons have higher health risks than the general population

Formerly incarcerated persons have higher health risks than the general population

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

International collaboration secures €1M grant to investigate new treatment target for lymphoma

International collaboration secures €1M grant to investigate new treatment target for lymphoma

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

MDC researchers develop a potent weapon against lymphomas

MDC researchers develop a potent weapon against lymphomas

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

FDA provides update on adverse events associated with breast implants

FDA provides update on adverse events associated with breast implants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.